Lin Shen

26.8k total citations · 5 hit papers
487 papers, 15.4k citations indexed

About

Lin Shen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Lin Shen has authored 487 papers receiving a total of 15.4k indexed citations (citations by other indexed papers that have themselves been cited), including 308 papers in Oncology, 207 papers in Pulmonary and Respiratory Medicine and 142 papers in Surgery. Recurrent topics in Lin Shen's work include Gastric Cancer Management and Outcomes (139 papers), Colorectal Cancer Treatments and Studies (104 papers) and Cancer Immunotherapy and Biomarkers (85 papers). Lin Shen is often cited by papers focused on Gastric Cancer Management and Outcomes (139 papers), Colorectal Cancer Treatments and Studies (104 papers) and Cancer Immunotherapy and Biomarkers (85 papers). Lin Shen collaborates with scholars based in China, United States and Japan. Lin Shen's co-authors include Yoon‐Koo Kang, Atsushi Ohtsu, Hyun Cheol Chung, Yung‐Jue Bang, Eric Van Cutsem, Akira Sawaki, Josef Rüschoff, A. Feyereislova, Florian Lordick and Julie Hill and has published in prestigious journals such as Science, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Lin Shen

455 papers receiving 15.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

2010 5.3k citations Hyun Cheol Chung, Lin Shen et al. profile →
Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells

2020 940 citations Lin Shen et al. profile →
Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

2013 379 citations Jaffer A. Ajani, Hyun Cheol Chung et al. profile →
Fifteen-Year Effects of Helicobacter pylori, Garlic, and Vitamin Treatments on Gastric Cancer Incidence and Mortality

2012 344 citations Lin Shen et al. profile →
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study

2018 336 citations Lin Shen, Manish A. Shah et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Lin Shen	7.4k	7.1k	4.2k	4.1k	2.4k	487	15.4k
Manish A. Shah	8.9k 1.2×	8.0k 1.1×	5.2k 1.2×	4.1k 1.0×	2.2k 0.9×	336	17.3k
Sun Young Rha	7.8k 1.1×	8.9k 1.3×	3.4k 0.8×	6.3k 1.5×	1.6k 0.7×	710	17.9k
Jiafu Ji	4.3k 0.6×	5.3k 0.8×	3.0k 0.7×	5.5k 1.3×	1.9k 0.8×	486	14.4k
Patrick Schöffski	9.6k 1.3×	9.5k 1.4×	3.2k 0.8×	4.8k 1.2×	2.7k 1.1×	510	19.4k
Yoshihiro Kakeji	5.3k 0.7×	6.3k 0.9×	6.1k 1.5×	3.8k 0.9×	1.6k 0.7×	699	14.9k
Won Ki Kang	5.9k 0.8×	6.0k 0.9×	3.6k 0.9×	2.6k 0.6×	2.0k 0.8×	350	12.1k
Stefano Cascinu	11.2k 1.5×	7.3k 1.0×	3.4k 0.8×	4.2k 1.0×	1.1k 0.5×	648	18.3k
Hideo Baba	8.7k 1.2×	5.8k 0.8×	6.2k 1.5×	6.5k 1.6×	1.3k 0.5×	776	20.7k
Donato Nitti	5.9k 0.8×	3.3k 0.5×	4.2k 1.0×	3.3k 0.8×	948 0.4×	326	13.7k
J. Milburn Jessup	11.9k 1.6×	5.4k 0.8×	4.3k 1.0×	6.2k 1.5×	1.4k 0.6×	144	20.7k

Countries citing papers authored by Lin Shen

Since Specialization

Citations

This map shows the geographic impact of Lin Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lin Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lin Shen more than expected).

Fields of papers citing papers by Lin Shen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lin Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lin Shen. The network helps show where Lin Shen may publish in the future.

Co-authorship network of co-authors of Lin Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Lin Shen. A scholar is included among the top collaborators of Lin Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lin Shen. Lin Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yu, Xianjun, Xiaofeng Zhang, J. J. Liu, et al.. (2024). 132MO Anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC): Updated results from a phase I study. Annals of Oncology. 35. S1456–S1456. 2 indexed citations

Wu, Min, et al.. (2024). Clinical and splenectomy-based treatment outcomes in 40 cases of hepatosplenic T-cell lymphoma: a comprehensive analysis. World Journal of Surgical Oncology. 22(1). 330–330.

Rong, Li, Shunle Li, Lin Shen, et al.. (2024). LINC00618 facilitates growth and metastasis of hepatocellular carcinoma via elevating cholesterol synthesis by promoting NSUN2-mediated SREBP2 m5C modification. Ecotoxicology and Environmental Safety. 285. 117064–117064. 10 indexed citations

Sun, Jong‐Mu, Antoine Adenis, Peter C. Enzinger, et al.. (2024). LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma. Future Oncology. 20(35). 2709–2721. 2 indexed citations

Yao, Hong, Hang Liu, Lin Shen, et al.. (2023). Quinoline-based anti-MRSA agents: Current development, structure-activity relationships, and mechanisms. Chinese Chemical Letters. 35(1). 108511–108511. 9 indexed citations

Zhang, Qi, Jian Zhang, Haijun Zhong, et al.. (2023). Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma. Cancer Immunology Immunotherapy. 72(8). 2729–2739. 1 indexed citations

Shen, Lin, Min Wu, Pingping Chen, et al.. (2023). Maintenance regimen of GM‐CSF with rituximab and lenalidomide improves survival in high‐risk B‐cell lymphoma by modulating natural killer cells. Cancer Medicine. 12(12). 12975–12985. 3 indexed citations

Qi, Changsong, Liangzheng Chang, Jiyao Li, et al.. (2023). 1018O Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer. Annals of Oncology. 34. S620–S620. 2 indexed citations

Xu, Ting, Jian Li, Zhenghang Wang, et al.. (2023). Real‐world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer. Cancer Medicine. 12(9). 10473–10484. 9 indexed citations

10.

Shen, Lin, Ningning Li, Weijian Guo, et al.. (2023). 1524P First-line TST001 plus capecitabine and oxaliplatin (CAPOX) for advanced G/GEJ cancer with CLDN18.2 positive overall survival data from study transtar102-Cohort C. Annals of Oncology. 34. S858–S859. 3 indexed citations

11.

Lordick, Florian, Manish A. Shah, Kohei Shitara, et al.. (2023). 134MO Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. Annals of Oncology. 34. S1524–S1524. 2 indexed citations

12.

Wang, Dong, Aimin Zang, Jing Wang, et al.. (2022). Phase 2 study of tislelizumab monotherapy in previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors: Gynecological cancer subgroup (127). Gynecologic Oncology. 166. S80–S81.

13.

Catenacci, Daniel V.T., Minori Koshiji Rosales, Hyun Cheol Chung, et al.. (2021). P-138 Margetuximab combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction or gastric cancer. Annals of Oncology. 32. S146–S146. 1 indexed citations

14.

Peng, Zhi, Siyuan Cheng, Yan Kou, et al.. (2020). The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer. Cancer Immunology Research. 8(10). 1251–1261. 235 indexed citations

15.

Cao, Yanshuo, Yutong Ma, Jiangyuan Yu, et al.. (2020). Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide‐induced high tumor mutational burden. Cancer Communications. 40(12). 746–751. 19 indexed citations

16.

Li, Yilin, Xiaotian Zhang, Dan Liu, et al.. (2018). Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance. Clinical Cancer Research. 24(21). 5261–5271. 46 indexed citations

17.

Shen, Lin, et al.. (2018). A retrospective study of concurrent chemoradiotherapy plus S-1 adjuvant chemotherapy on curative effect for treatment of patients with N3 stage nasopharyngeal carcinoma. SHILAP Revista de lepidopterología. 1 indexed citations

18.

Yu, Dan, Shasha Gao, & Lin Shen. (2017). The Empirical Study of the Education Investment’s Influences on the Industrial Structure Rationalization in Hainan Province. Journal of Service Science and Management. 10(5). 447–463. 2 indexed citations

19.

Q, Guo, et al.. (2016). Benefit of percutaneous endoscopic gastrostomy in patients undergoing definitive chemoradiotherapy for locally advanced nasopharyngeal carcinoma. SHILAP Revista de lepidopterología.

20.

Peng, Zhi, Zhongwu Li, Jing Gao, et al.. (2015). Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. Molecular Cancer Therapeutics. 14(11). 2634–2641. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact